Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 5, 2010, Pages 795-798

  Shimodaira, Hideki ^a,b   Komine, Keigo ^a,b   Soeda, Hiroshi ^a,b   Ishioka, Chikashi ^a,b  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

ADCC; Anti EGFR antibody

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FC RECEPTOR; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CYTOLYSIS; DISEASE MARKER; DNA POLYMORPHISM; DRUG EFFICACY; MOLECULARLY TARGETED THERAPY; PREDICTIVE VALUE; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 79960765258     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Lammerts van Bueren JJ, Bleeker WK, Brannstrom A, et al: The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci USA 105:6109-6114, 2008.
2. Kawaguchi Y, Kono K, Mimura K, et al: Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 120:781-787, 2007. (Pubitemid 46175397)
3. Kimura H, Sakai K, Arao T, et al: Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 98:1275-1280, 2007. (Pubitemid 46993549)
4. Kurai J, Chikumi H, Hashimoto K, et al: Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 13:1552-1561, 2007.
5. Peipp M, Schneider-Merck T, Dechant M, et al: Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. J Immunol 180:4338-4345, 2008.
6. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, et al: Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but. in contrast to IgG1, only by cells of myeloid lineage. J Immunol 184:512-520, 2010.
7. Jefferis R: Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 7:1401-1413, 2007.
8. Maxwell KF, Powell MS, Hulett MD, et al: Crystal structure of the human leukocyte Fc receptor, FcγR II a. Nat Struct Biol 6:437-442, 1999. (Pubitemid 29218012)
9. Sondermann P, Huber R, Oosthuizen V, et al: The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaR III complex. Nature 406:267-273, 2000. (Pubitemid 30604397)
10. Sibéril S, Dutertre CA. Fridman WH, et al: FcγR: The key to optimize therapeutic antibodies ? Crit Rev Oncol Hematol 62:26-33, 2007.
11. Koene HR, Kleijer M, Algra J, et al: FcγR III a-158 V/F polymorphism influences the binding of IgG by natural killer cell FcγR III a, independently of the FcγR III a-48 L/ R/H phenotype. Blood 90:1109-1114, 1997. (Pubitemid 27314146)
12. Clynes RA, Towers TL, Presta LG, et al: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446, 2000. (Pubitemid 30208162)
13. Gennari R, Menard S, Fagnoni F, et al: Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10:5650-5655, 2004. (Pubitemid 39180938)
14. Musolino A, Naldi N, Bortesi B, et al: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/ neu-positive metastatic breast cancer. J Clin Oncol 26:1789-1796, 2008.
15. Di Gaetano N, Cittera E, Nota R. et al: Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171:1581-1587, 2003. (Pubitemid 36900094)
16. Cartron G, Dacheux L, Salles G, et al: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγR III a gene. Blood 99:754-758, 2002. (Pubitemid 34525533)
17. Weng WK and Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947, 2003.
18. Zhang W, Gordon M, Schultheis AM, et al: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25:3712-3718, 2007. (Pubitemid 47372612)
19. Bibeau F, Lopez-Crapez E, Di Fiore F, et al: Impact of FcγR II a-FcγR la polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27:1122-1129, 2009.
20. Lopez-Albaitero A, Lee SC, Morgan S, et al: Role of polymorphic Fc gamma receptor III a and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 58:1853-1864, 2009.
21. 1 variants with improved binding to the FcγR. J Biol Chem 276:6591-6604, 2001.
22. 1 N-linked oligosaccharide improves binding to human FcγR III and antibody-dependent cellular toxicity. J Biol Chem 277:26733-26740, 2002. (Pubitemid 34951677)